Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGC-AD1 Safety in Alzheimer's Dementia
NCT04749563Phase 1Completed
- Sponsor
- IGC Pharma
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IGC-AD1 in Alzheimer's disease (AD) (2 arms), sponsored by IGC Pharma. Primary endpoint: Incidence of treatment-emergent adverse events at 3 weeks. Started Jan 2021; status: completed.
02
Drugs
IGC-AD1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04749563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04749563.